<prompt> In PML, all of the following are seen except :Retinoic acid is used in treatment1517 translocationCD 1534 both seen in same cellAssociated with DIVC  <response>: Answer is C CD15 34 both seen in same cell Acute promyelocytic Leukaemia PML : FAB M3 This is a type of Acute Myeloid Leukaemia AML and has been classified as the M3 category according to the FAB morphological classification.9 It constitutes 5 - 10 of all AML Robbins Ghai Pathological characteristic of PML It is characterized by the chromosomal translocation 115;17Q - CMDT t1 5;17 translocation produces a fusion gene PML-RAR involving the Retinoic Acid Receptor gene and Promyelocytic Leukemia PML gene. This PML - RaR fusion protein tends to suppress gene transcription and blocks differentiation of cells. This block can be overcome with pharmacological doses of retinoic acid Harrrison. Most cells are hypergranularQ promyelocytes often with many Auer rods per cell. Presentation characteristic Specific features of PML Patients of PML are younger median age 35 - 40 years - Robbins Incidence of Disseminated Intravascular Coagulation DIVC is high in patient with PML. -Robbins DIC may occur with any subgroup of AML but is especially common in acute PML M3-Ghai Treatment specific to PML subject All-Trans Retinoic Acid ATRATretinoin The treatment of patient with PML has been dramatically improved by the use of All - Trans - Retinoic acid. This agent is an analog of vitamin A that leads to terminal differentiation of occult promyelocytic leukemia cells. - CMDT Remission in PML is induced by All - Trans-Retinoic acid as a single agent -Ghai Arsenic Trioxide Arsenic Trioxide produces meaningful response in upto 85 of patients refractory to tretinoin 